HNSP.F Stock Overview
An investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Hansoh Pharmaceutical Group Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$2.70 |
| 52 Week High | HK$5.58 |
| 52 Week Low | HK$1.95 |
| Beta | 0.66 |
| 1 Month Change | -21.74% |
| 3 Month Change | 10.20% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 47.54% |
Recent News & Updates
Recent updates
Shareholder Returns
| HNSP.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 1.8% | 0.5% |
| 1Y | n/a | -10.1% | 11.1% |
Return vs Industry: Insufficient data to determine how HNSP.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how HNSP.F performed against the US Market.
Price Volatility
| HNSP.F volatility | |
|---|---|
| HNSP.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 11.4% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: HNSP.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine HNSP.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 8,989 | Huijuan Zhong | www.hspharm.com |
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Fulairui, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and with Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist.
Hansoh Pharmaceutical Group Company Limited Fundamentals Summary
| HNSP.F fundamental statistics | |
|---|---|
| Market cap | US$18.87b |
| Earnings (TTM) | US$606.57m |
| Revenue (TTM) | US$1.70b |
Is HNSP.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HNSP.F income statement (TTM) | |
|---|---|
| Revenue | CN¥12.26b |
| Cost of Revenue | CN¥1.12b |
| Gross Profit | CN¥11.14b |
| Other Expenses | CN¥6.77b |
| Earnings | CN¥4.37b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.74 |
| Gross Margin | 90.89% |
| Net Profit Margin | 35.66% |
| Debt/Equity Ratio | 0.1% |
How did HNSP.F perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/21 17:13 |
| End of Day Share Price | 2025/05/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hansoh Pharmaceutical Group Company Limited is covered by 34 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bo Li | BofA Global Research |
| Jin Zhang | China International Capital Corporation Limited |
| Ziyu He | China International Capital Corporation Limited |